Christopher Scott Rose

Christopher Scott Rose

Auto-generated profile, based on publicly available information

Christopher Scott Rose

Radiotherapy Physics, South West Wales Cancer Centre, Swansea Bay University Health Board, Swansea, Wales, UK

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in Journal of Radiotherapy in Practice
Verified
Journal Article
Open access
PDF file
JPJoseph Purden
Joseph Purden
DEDouglas Etheridge
Douglas Etheridge
CRChristopher Rose
Christopher Rose
GRGenotan Reggian
Genotan Reggian
ATAndrea Tales
Andrea Tales
RLRyan Lewis
Ryan Lewis
Background: Geographical inequalities in cancer care, often termed the ‘postcode lottery’, have long affected patient access and outcomes across the UK. In Wales, radiotherapy services are concentrated within three specialist centres, meaning many patients must travel considerable distances for treatment, potentially extending the time between key steps in the pathway. This study examined whether distance from the South-West Wales Cancer Centre (SWWCC) influenced access to, or timing of, breast cancer radiotherapy and explored whether and how service developments have mitigated geographic inequity. Methods: A retrospective cohort analysis was performed on 2,286 breast cancer patients treated at SWWCC between January 2018 and December 2023. Patients were grouped by travel time (≤60 min vs >60 min), transport type and treatment prescription. Statistical analyses, including Fisher’s exact and Kruskal-Wallis tests, assessed associations between travel distance, transport modality and treatment timing. Results: 31% of patients lived more than 60 minutes away and were significantly more likely to require ambulance transport (16.8% vs 4.4%) or hostel accommodation (11.3% vs 0%) ( p < .001). There was no statistically significant difference in time from booking to first treatment fraction ( p = .676). Mean CT-to-plan-check intervals fell from 27 to <10 days, and the wait between booking and start of treatment fell from ∼60 to 25 days, reflecting efficiency gains linked to capacity release from adoption of hypofractionated regimens. Conclusions: Treatment timeliness is equitable across South-West Wales. Five-fraction regimens have alleviated many postcode-related disparities, though differences in transport dependence and access to supportive services remain areas for improvement.

27 July 2026 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
DEDouglas Etheridge
Douglas Etheridge
RLRyan David Lewis
Ryan David Lewis
AAAdam Henry Aitkenhead
Adam Henry Aitkenhead
CRChristopher Scott Rose
Christopher Scott Rose
NPNathan Proudlove
Nathan Proudlove
At the South West Wales Cancer Centre, breast radiotherapy accounts for 24% of the radiotherapy workload. In 2021, only 16% of patients started treatment within 14 days compared with the Welsh time-to-radiotherapy quality metric target of 80%. Delays risk poorer outcomes for patients and create inefficiencies as tasks are often batched and staff alternate between idle and peak workload periods. Earlier analysis showed that only 1%–2% of the overall breast radiotherapy pathway time was value-adding activity. Key delays occurred at several stages of the pathway, where the total duration of each stage, including time spent waiting in the queue and time actively worked on, averaged around 50% longer than scheduled. For example, CT simulation was typically scheduled for 2 days but took more than 4 days while organ at risk (OAR) delineation was scheduled for 2 days but took approximately 2.5 days. Our improvement strategy targeted these delays through: (1) expansion of the technologist plan approval (TPA) pathway, (2) introduction of daily workflow meetings and clearer, standardised planning protocols and (3) implementation of artificial intelligence (AI) auto-contouring for OAR delineation. These changes were tested using the Model for Improvement, with statistical process control monitoring of metrics plus staff feedback. The mean total radiotherapy breast pathway time from consent-to-treatment decreased from 19.5 days to 14.8 days, with patients commencing treatment within 14 days increasing from 16% to 55%. Use of the TPA pathway increased from 61% to 95% and plan queries reduced from 11% to 3%, reducing oncologist workload. Daily workflow meetings and improved protocols reduced average planning times from 4 days to 1.5 days and were valued by staff for improving workload equity and team cohesion. AI auto-contouring reduced OAR delineation from 2.3 to 0.6 days, though ongoing validation of contour quality is required.